SCHEMBL11951599

SCHEMBL11951599

CCn1cnc(-c2ccc(C(C)C)cc2C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 2/20 0.42
▸ CYP2C9 P11712 2/20 0.42
▸ CYP2C19 P33261 2/20 0.42
▸ CYP2E1 P05181 1/20 0.42
▸ CYP2A6 P11509 1/20 0.42
▸ CYP2B6 P20813 1/20 0.42
▸ LMNA P02545 2/20 0.42
▸ PDE3B Q13370 1/20 0.35
▸ PDE3A Q14432 1/20 0.35
▸ CRHR1 P34998 2/20 0.35
▸ ACHE P22303 2/20 0.35
▸ BCHE P06276 1/20 0.35
▸ TRPA1 O75762 1/20 0.34
▸ PTGS1 P23219 1/20 0.34
▸ CACNA1C Q13936 1/20 0.34
▸ IRAK4 Q9NWZ3 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.32
▸ CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11962891 0.81 CYP3A4 (0.46) CYP3A4CYP2C9CYP2C19CYP2E1CYP2A6
SCHEMBL18730149 0.71 LMNA (0.50) LMNACRHR1ACHEBCHETRPA1
SCHEMBL20676163 0.71 LMNA (0.77) LMNAACHEBCHETRPA1PTGS1
SCHEMBL27420837 0.70 KDM5A (0.45) CYP3A4CYP2C9CYP2C19CYP2E1CYP2A6
SCHEMBL11951600 0.69 LMNA (0.47) LMNATRPA1PTGS1CACNA1CHTT
SCHEMBL13380080 0.69 LMNA (0.47) LMNATRPA1PTGS1CACNA1CHTT
SCHEMBL10416092 0.67 LMNA (0.86) LMNAACHEBCHETRPA1PTGS1
SCHEMBL11951638 0.67 LMNA (0.44) LMNAIRAK4
SCHEMBL25494305 0.67 LMNA (0.41) LMNATRPA1PTGS1CACNA1CIRAK4
SCHEMBL13380076 0.66 LMNA (0.52) LMNAPDE3BPDE3ATRPA1PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170145011-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMA (US) 2017-05-25 — — US disclosed
US-20170145011-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMA (US) 2017-05-25 — — US disclosed
US-9511067-B2 Substituted spiro[piperidine-4,1'-pyrrolo[1,2-a]pyrazine]s as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2016-12-06 — — US disclosed
US-20150174127-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS (SAN DIEGO) LLC 2015-06-25 — — US disclosed
US-8916565-B2 Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-12-23 — — US disclosed
US-20120196869-A1 PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2012-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174127-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels KCNJ2, KCNJ5, KCNJ1 CYP3A4 3620/4885CYP2C9 4046/4885CYP2C19 3941/4885
US-20170145011-A1 Pyrrolopyrazine-Spirocyclic piperidine amides as modulators of ion channels KCNJ2, KCNJ5, KCNJ1 CYP3A4 3620/4885CYP2C9 4046/4885CYP2C19 3941/4885
US-20120196869-A1 PYRROLOPYRAZINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS KCNJ2, KCNJ5, KCNJ1 CYP3A4 3620/4885CYP2C9 4046/4885CYP2C19 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback